35 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
7837233	21	CCK-A receptor selective antagonists derived from the CCK-A receptor selective tetrapeptide agonist Boc-Trp-Lys(Tac)-Asp-MePhe-NH2 (A-71623).	Glaxo Research Institute
9057851	30	Structure-based design of new constrained cyclic agonists of the cholecystokinin CCK-B receptor.	University of Paris
8831778	22	The use of topographical constraints in receptor mapping: investigation of the topographical requirements of the tryptophan 30 residue for receptor binding of Asp-Tyr-D-Phe-Gly-Trp-(N-Me)Nle-Asp-Phe-NH2 (SNF 9007), a cholecystokinin (26-33) analogue that binds to both CCK-B and delta-opioid recepto	University of Arizona
8126703	29	Tetrapeptide CCK-A agonists: effect of backbone N-methylations on in vitro and in vivo CCK activity.	Abbott Laboratories
8295219	44	Tetrapeptide CCK agonists: structure-activity studies on modifications at the N-terminus.	Abbott Laboratories
8201591	2	CCK-A-selective tetrapeptides containing lys(N epsilon)-amide residues: favorable in vivo and in vitro effects of N-methylation at the aspartyl residue.	Abbott Laboratories
8421283	43	CCK-B agonist or antagonist activities of structurally hindered and peptidase-resistant Boc-CCK4 derivatives.	University of Paris
1375964	112	Development of potent and selective CCK-A receptor agonists from Boc-CCK-4: tetrapeptides containing Lys(N epsilon)-amide residues.	Abbott Laboratories
2299627	54	Novel glutamic acid derived cholecystokinin receptor ligands.	Merck Sharp & Dohme Research Laboratories
1700123	26	Development of CCK-tetrapeptide analogues as potent and selective CCK-A receptor agonists.	Abbott Laboratories
2885419	179	Design of nonpeptidal ligands for a peptide receptor: cholecystokinin antagonists.	TBA
14698161	10	Synthesis and biological characterisation of [3H]BBL454, a new CCK2 selective radiolabelled agonist displaying original pharmacological properties.	University of Paris
	32	Pseudopeptide CCK-4 analogues incorporating the [CH(CN)NH] peptide bond surrogate	TBA
	66	Amino acid-derived piperidides as novel CCKB ligands with anxiolytic-like properties	TBA
	42	A water soluble benzazepine cholecystokinin-B receptor antagonist	TBA
	58	5,7-Diphenyl-3-ureidohexahydroazepin-2-ones as Cholecystokinin-B receptor ligands	TBA
	28	Toward developing peptidomimetics: Successful replacement of backbone amide bonds in tetrapeptide-based CCK-A receptor agonists	TBA
	16	Structure-based design and pharmacological properties of potent selective and systemically active CCK-B peptidomimetics	TBA
19261479	21	Anthranilic acid based CCK1 receptor antagonists: blocking the receptor with the same 'words' of the endogenous ligand.	University of Trieste
17368898	6	Synthesis and evaluation of novel benzimidazole derivative [Bz-Im] and its radio/biological studies.	Lucknow University
11020275	75	Replacement of glycine with dicarbonyl and related moieties in analogues of the C-terminal pentapeptide of cholecystokinin: CCK(2) agonists displaying a novel binding mode.	University of Paris
9871777	28	Novel constrained CCK-B dipeptoid antagonists derived from pipecolic acid.	University of Paris
9089338	29	Minor structural differences in Boc-CCK-4 derivatives dictate affinity and selectivity for CCK-A and CCK-B receptors.	Abbott Laboratories
8411002	67	Cholecystokinin peptidomimetics as selective CCK-B antagonists: design, synthesis, and in vitro and in vivo biochemical properties.	University of Paris
8201590	20	Novel Asp32-replacement tetrapeptide analogues as potent and selective CCK-A agonists.	Abbott Laboratories
7966138	55	5-Phenyl-3-ureidobenzazepin-2-ones as cholecystokinin-B receptor antagonists.	Pfizer
2724293	28	Synthesis and binding affinities of cyclic and related linear analogues of CCK8 selective for central receptors.	University of Paris
2704023	20	Hybrid cholecystokinin (CCK) antagonists: new implications in the design and modification of CCK antagonists.	Abbott Laboratories
2464062	10	Full agonists of CCK8 containing a nonhydrolyzable sulfated tyrosine residue.	University of Paris
1992147	10	trans-3-n-propyl-L-proline is a highly favorable, conformationally restricted replacement for methionine in the C-terminal tetrapeptide of cholecystokinin. Stereoselective synthesis of 3-allyl- and 3-n-propyl-L-proline derivatives from 4-hydroxy-L-proline.	Abbott Laboratories
1766000	90	Cholecystokinin antagonists: (R)-tryptophan-based hybrid antagonists of high affinity and selectivity for CCK-A receptors.	Abbott Laboratories
1716682	64	Boc-CCK-4 derivatives containing side-chain ureas as potent and selective CCK-a receptor agonists.	Abbott Laboratories
1701834	20	Boc-Trp-Orn(Z)-Asp-NH2 and derivatives: a new family of CCK antagonists.	University of Paris
1501220	52	Synthesis and biological activity of CCK heptapeptide analogues. Effects of conformational constraints and standard modifications on receptor subtype selectivity, functional activity in vitro, and appetite suppression in vivo.	Abbott Laboratories
1495013	24	N-methylated analogs of Ac[Nle28,31]CCK(26-33): synthesis, activity, and receptor selectivity.	Hadassah-University Hospital